Product Datasheet

GSK561679

Catalog No. **BP-02097** · CAS **885220-61-1** · Form **free base** · Physical state **other** · Color **white to off-white** · Version **1.0** · Revision **2026-09-14**

FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.

Target	Research area
CRFR	**Neurological Disease; Endocrinology**

Molecular formula	$C_{22}H_{26}N_6O_2$
Molecular weight	**406.4808**

STRUCTURE



DESCRIPTION

Verucerfont (GSK561679) is a corticotropin-releasing factor receptor 1 (CRF1) antagonist with IC50s of ~6.1, >1000 and >1000 nM for CRF1, CRF2, and CRF-BP, respectively.

BIOLOGICAL ACTIVITY

In Vivo

Post hoc analysis shows that the prototypic non-peptide CRF1 receptor antagonist NBI30775 (R121919) and Verucerfont are both significantly different from vehicle, CP-316?311, and pexacerfont (P<0.001 for all comparisons collapse across time-points); the latter three treatments in turn do not differ from each other. A differential effect of treatments over time is also shown by a significant treatment×time interaction (F[20,140]=6.4, P<0.001). Accordingly, detailed Post hoc analysis shows that both NBI30775 and Verucerfont inhibit ACTH release throughout the following 6?h of measurement (P<0.001 vs vehicle at each time-point, and vs the respective pretreatment baseline)

SOLUBILITY

Soluble in DMSO

In vitro	DMSO : 83.33 mg/mL

REFERENCES

[1]. Schwandt ML, et al. The CRF1 Antagonist Verucerfont in Anxious Alcohol-Dependent Women: Translation of Neuroendocrine, But not of Anti-Craving Effects. Neuropsychopharmacology. 2016 Nov;41(12):2818-2829.